Matthias Cavassini
Matthias Cavassini
Head of the Infectious Diseases outpatient clinic, CHUV, Lausanne, Switzerland
Verified email at chuv.ch
Title
Cited by
Cited by
Year
Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study
S Collins, T Mertenskoetter, E Loeliger, R Tressler, I Weller, N Friis-Mųller, ...
Archives of internal medicine 166 (15), 1632-1641, 2006
13322006
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration
D: A: D Study Group
The Lancet 371 (9622), 1417-1426, 2008
10172008
Cognitive dysfunction in HIV patients despite long-standing suppression of viremia
S Simioni, M Cavassini, JM Annoni, AR Abraham, I Bourquin, V Schiffer, ...
Aids 24 (9), 1243-1250, 2010
6832010
Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis
AJ Nordmann, M Briel, HC Bucher
European heart journal 27 (23), 2784-2814, 2006
6532006
Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study
B Hasse, B Ledergerber, H Furrer, M Battegay, B Hirschel, M Cavassini, ...
Clinical Infectious Diseases 53 (11), 1130-1139, 2011
5752011
Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART study
Strategies for Management of Antiretroviral Therapy (SMART) Study Group
The Journal of infectious diseases 197 (8), 1133-1144, 2008
5342008
Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
A Trickey, MT May, JJ Vehreschild, N Obel, MJ Gill, HM Crane, ...
The lancet HIV 4 (8), e349-e356, 2017
4662017
Dominant TNF-α+ Mycobacterium tuberculosis–specific CD4+ T cell responses discriminate between latent infection and active disease
A Harari, V Rozot, FB Enders, M Perreau, JM Stalder, LP Nicod, ...
Nature medicine 17 (3), 372-376, 2011
3852011
Decreasing mortality and changing patterns of causes of death in the S wiss HIV C ohort S tudy
R Weber, M Ruppik, M Rickenbach, A Spörri, H Furrer, M Battegay, ...
HIV medicine 14 (4), 195-207, 2013
3712013
Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to< 500 Cells/µL in HIV Type 1—Infected Individuals Receiving Potent Antiretroviral Therapy
GR Kaufmann, H Furrer, B Ledergerber, L Perrin, M Opravil, P Vernazza, ...
Clinical infectious diseases 41 (3), 361-372, 2005
3682005
Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV‐infected Individuals
M Rotger, H Tegude, S Colombo, M Cavassini, H Furrer, L Decosterd, ...
Clinical pharmacology & therapeutics 81 (4), 557-566, 2007
2772007
Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study
B Ledergerber, H Furrer, M Rickenbach, R Lehmann, L Elzi, B Hirschel, ...
Clinical Infectious Diseases 45 (1), 111-119, 2007
2732007
PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals
R Banga, FA Procopio, A Noto, G Pollakis, M Cavassini, K Ohmiti, ...
Nature medicine 22 (7), 754-761, 2016
2702016
Changing patterns of cancer incidence in the early-and late-HAART periods: the Swiss HIV Cohort Study
S Franceschi, M Lise, GM Clifford, M Rickenbach, F Levi, M Maspoli, ...
British journal of cancer 103 (3), 416-422, 2010
2672010
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial
J Ananworanich, A Gayet-Ageron, M Le Braz, W Prasithsirikul, ...
The Lancet 368 (9534), 459-465, 2006
2672006
Evaluation of MRSA-Screen, a simple anti-PBP 2a slide latex agglutination kit, for rapid detection of methicillin resistance in Staphylococcus aureus
M Cavassini, A Wenger, K Jaton, DS Blanc, J Bille
Journal of Clinical Microbiology 37 (5), 1591-1594, 1999
2641999
Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America
Antiretroviral Therapy Cohort Collaboration
Clinical Infectious Diseases 41 (12), 1772-1782, 2005
2542005
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral …
FA Post, GJ Moyle, HJ Stellbrink, P Domingo, D Podzamczer, M Fisher, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 55 (1), 49-57, 2010
2452010
Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and-adherent patients
KJ Metzner, SG Giulieri, SA Knoepfel, P Rauch, P Burgisser, S Yerly, ...
Clinical infectious diseases 48 (2), 239-247, 2009
2412009
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active …
A Mills, JR Arribas, J Andrade-Villanueva, G DiPerri, J Van Lunzen, ...
The Lancet Infectious Diseases 16 (1), 43-52, 2016
2382016
The system can't perform the operation now. Try again later.
Articles 1–20